(Q44110705)

29 November 2017

Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area (English)

1 reference

29 November 2017

0 references

Norbert Bräu

1

1 reference

29 November 2017

Edmund J Bini

2

1 reference

29 November 2017

Azra Shahidi

3

1 reference

29 November 2017

Ayse Aytaman

4

1 reference

29 November 2017

Peiying Xiao

5

1 reference

29 November 2017

Saray Stancic

6

1 reference

29 November 2017

Robert Eng

7

1 reference

29 November 2017

Sheldon T Brown

8

1 reference

29 November 2017

Fiorenzo Paronetto

9

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

The American Journal of Gastroenterology

29 November 2017

1 reference

29 November 2017

97

1 reference

29 November 2017

8

1 reference

29 November 2017

2071-2078

1 reference

Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users

29 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Hepatitis C in France: a national survey in the Departments of Internal Medicine and Infectious Diseases. The GERMIVIC (Joint Study Group on Hepatitis C virus of the French National Society of Internal Medicine and the French Society of Infectious D

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Prevalence of hepatitis C virus seropositivity among hospitalized US veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

45-year follow-up of hepatitis C virus infection in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Incubation period of AIDS in San Francisco

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05924.X

10.1111/J.1572-0241.2002.05924.X

21 January 2018

Identifiers

DOI

1 reference

release_e6ed7ewc5fabrdjy74hlejuney

29 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e6ed7ewc5fabrdjy74hlejuney

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference